BackLandos Biopharma Overview

Landos Biopharma Other Assets

Landos Biopharma's other assets is $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer average

Loading

Landos Biopharma Other Assets History

Loading

Landos Biopharma vs. peers: Other Assets Comparison

Loading

Landos Biopharma Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Landos Biopharma (LABP) FAQ

Landos Biopharma (LABP) currently reports a other assets of $0 as of March 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Landos Biopharma's other assets history and peer comparisons.

Landos Biopharma's other assets changed from $0 to $0 (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Landos Biopharma reported $0 in other assets as of March 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other assets of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Landos Biopharma, and consider following LABP for alerts when major investors trade the stock.

Landos Biopharma is classified in the Healthcare sector. On other assets, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LABP with unrelated industries.